Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoid malignancy accounting for 30 %-40 % of all non-Hodgkin lymphoma (NHL). Young patients with high-risk DLBCL as a special group with poor clinical prognosis still can not receive standard treatment protocols in clinical practice at present. Conventional chemotherapy, combination of rituximab (R) to conventional CHOP chemotherapy, R-CHOP-like protocol, high-dose chemotherapy and autologous hematopoietic stem cell transplantation have not fully reversed the poor prognosis. This review focuses on the recent advances and future direction in the treatment of the young patients with high-risk DLBCL. Key words: Diffuse large B-cell lymphoma; Young patients; High-risk; Prognosis; Treatment
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
